Clinical trials: Sexually Transmitted Disease (STD)
HIV Infections
A Study of Anti-HIV Monoclonal Antibody KD-247
The purpose of this study is to evaluate the safety and tolerability of 3 infusions of KD-247 over 2 weeks in HIV-1 seropositive individuals; to determine the pharmacokinetic parameters of KD-247 when administered as above; and…
- Trial name
- NCT00917813
- Testing
- KD-247, Physiological saline
- Where
- 15 sites in United States
- Volunteers
- 27 people
- Sponsor
- The Chemo-Sero-Therapeutic Research Institute
HIV Infections, AIDS
Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with hypertriglyceridemia.
- Conditions
- HIV Infections, AIDS, Dyslipidemia, Hypertriglyceridemia
- Trial name
- NCT00346697
- Testing
- Omega-3 fatty acid administration
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Brown, Todd, M.D., Ph.D.
Gonorrhoea
Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea
This is a multi-center Phase 2 randomized, open-label study in approximately 180 adult male and female subjects, between the ages of 18 and 55, who are in good health and meet all eligibility criteria.
- Trial name
- NCT02257918
- Testing
- AZD0914, Ceftriaxone
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, HIV Infections
Study to Reduce Intravenous Exposures (STRIVE)
The purpose of this study is to determine whether a six-session, small group behavioral intervention based on "peer-volunteer activism" is effective in (1) decreasing distributive sharing of syringes and other injection…
- Trial name
- NCT00391482
- Testing
- Peer Mentoring Intervention for HCV-Infected IDUs
- Where
- 3 sites in United States
- Volunteers
- 750 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
HIV Infections, Treatment Naive
Intensive Viral Dynamics Substudy of A5248
The HIV integrase inhibitor, raltegravir (RAL), which was recently approved by the FDA, has been shown in several trials to be highly effective.
- Trial name
- NCT00852618
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cervical Precancer, Cervical Intraepithelial Neoplasia
Point of Care - Triage and Treatment for Cervical Pre-cancer
This study evaluates a modified two-probe thermal ablation protocol using the IRIS™ device and retrospectively assesses an AI-based Automated Visual Evaluation (AVE) triage algorithm among HPV-positive women in El Salvador.
- Conditions
- Cervical Precancer, Cervical Intraepithelial Neoplasia, Human Papillomavirus Infection
- Trial name
- POC (NCT07461818)
- Testing
- IRIS™ Thermal Ablation Device
- Where
- El Salvador
- Volunteers
- 5,000 people
- Sponsor
- Basic Health International, Inc.
Acquired Immunodeficiency Syndrome
Intervention for HIV-Positive Black Young Men Who Have Sex With Men (YMSM)
This study involves conducting formative research to develop a culturally appropriate secondary prevention intervention for HIV-positive Black young men who have sex with men (B-YMSM).
- Trial name
- NCT01502618
- Testing
- Focus Group
- Volunteers
- 18 people
- Sponsor
- University of North Carolina, Chapel Hill
Gonorrhea, Neisseria Gonorrhoeae
Washington State Community Expedited Partner Treatment (EPT) Trial
The Washington State Community Expedited Partner Therapy Trial is a stepped-wedge community level randomized trial designed to test the hypothesis that a public health program designed to increase the use of expedited partner…
- Conditions
- Gonorrhea, Neisseria Gonorrhoeae, Chlamydia Trachomatis
- Trial name
- NCT01665690
- Testing
- Patient delivered partner therapy, Targeted public health partner services
- Where
- 2 sites in United States
- Volunteers
- 33,222 people
- Sponsor
- University of Washington
HIV Infections
Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection
Pilot study to evaluate the impact of extremely early ART in the dynamics of viral reservoir, immune activation and inflammation in patients with HIV-1 infection of less than 20 days (Fiebig stages I-II) compared to patients with…
- Trial name
- VIRECURE (NCT02588820)
- Testing
- Antiretroviral Therapy (Experimental)
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- David Garcia Cinca
HIV Infections, Kidney Disease
Optimal Treatment for Kidney Disease in HIV Infected Adults
The angiotensin receptor blocker (ARB) valsartan is a drug commonly used to treat high blood pressure. Valsartan may also help slow down the progression of kidney disease in HIV infected people.
- Trial name
- NCT00089518
- Testing
- Valsartan
- Where
- 10 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Patient Commitment Preferences for Medication Adherence
Understanding Medication Adherence Among HIV Patients
In anticipation of a pilot study incorporating behavioral economics into the treatment of infectious diseases, we will conduct a survey with HIV/AIDS patients at the Ponce Clinic (Infectious Disease Program of Grady Memorial…
- Trial name
- NCT01305590
- Testing
- Survey to Understand Medication Adherence among HIV Patients
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Bureau of Economic Research, Inc.
HIV Infection
Neural Correlates of Working Memory Training for HIV Patients
Despite potent combination antiretroviral therapy, cognitive (memory and concentration) problems continue to occur in up to 50% of HIV-infected individuals, especially in older infected individuals, and those who abuse alcohol…
- Trial name
- NCT02602418
- Testing
- Adaptive WM CogMed Training, Nonadaptive WM CogMed Training
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of Hawaii
HIV/AIDS and Infections
A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).
RIO is a placebo-controlled double-blinded two arm prospective phase II randomised controlled trial . This study will test the use of broadly neutralising antibodies (bNAbs) in participants with treated primary HIV infection…
- Trial name
- RIO (NCT04319367)
- Testing
- Investigational Medicinal Product
- Where
- 12 sites in Denmark, United Kingdom
- Volunteers
- 72 people
- Sponsor
- Imperial College London
HIV-1
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
The purpose of this study is to evaluate the pharmacokinetics, safety and antiviral activity of rilpivirine (TMC278) 25 milligram (mg) or adjusted dose once daily in combination with an investigator-selected background regimen…
- Trial name
- NCT00799864
- Testing
- Rilpivirine, Zidovudine, Abacavir
- Where
- 17 sites in United States, India and 6 more
- Volunteers
- 54 people
- Sponsor
- Janssen Sciences Ireland UC
Syphilis Infection, Syphilis
Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT
This study is to test the Reveal® TP (Syphilis) antibody POCT (MedMira, Inc., Halifax, Nova Scotia) for its performance in an urban STI clinic in Vancouver, British Columbia and compare its performance in parallel with the usual…
- Conditions
- Syphilis Infection, Syphilis, Early Syphilis, Symptomatic
- Trial name
- NCT05831098
- Testing
- Reveal TP (Syphilis) Antibody Test
- Where
- Canada
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- MedMira Laboratories Inc.
HIV/AIDS
VITAL Start: Brief Facility-based Video Intervention
This a multi-center, parallel group, randomized controlled outcome assessor blinded trial with a qualitative descriptive component that seeks to assess the effectiveness of a brief facility-based video intervention to optimize…
- Trial name
- VITAL (NCT03654898)
- Testing
- VITAL Start: Video-based pre-ART counseling, Standard of Care
- Where
- Malawi
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
HIV Infections
Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide
Vaginal microbicides are compounds that may protect women from HIV and other sexually transmitted infections (STIs). This study will determine the safety of the microbicide UC-781 by comparing the effects of keeping the…
- Trial name
- NCT00441909
- Testing
- UC-781
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS and Infections
POSSE Project: A Community-Level Intervention for Black YMSM
Black young men who have sex with men (BYMSM) are at high risk for contracting and transmitting HIV, and represent a priority population for developing effective interventions.
- Trial name
- NCT03198663
- Testing
- POSSE
- Where
- 2 sites in United States
- Volunteers
- 1,037 people, healthy volunteers welcome
- Sponsor
- Cook County Health
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants
The primary objectives of this study are to evaluate the safety, tolerability and steady-state PK and confirm the dose of EVG/r in HIV-1 infected, antiretroviral treatment-experienced children 4 weeks to <18 years of age.
- Trial name
- NCT01923311
- Testing
- EVG, Background regimen
- Where
- 11 sites in United States, Italy and 4 more
- Volunteers
- 31 people
- Sponsor
- Gilead Sciences
HIV Infections, Proteinuria
Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria
The study is designed to evaluate the proportion of patients with tenofovir induced proteinuria that will resolve their proteinuria when the tenofovir containing nucleoside/nucleotide backbone is switched to a raltegravir…
- Trial name
- RALPIR (NCT01044771)
- Testing
- change from tenofovir to raltegravir
- Volunteers
- 20 people
- Sponsor
- Metropolis Medical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.